M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 6.18 USD -3.74% Market Closed
Market Cap: 208.2m USD
Have any thoughts about
Myomo Inc?
Write Note

Myomo Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Myomo Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Additional Paid In Capital
$105.8m
CAGR 3-Years
6%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Additional Paid In Capital
$21B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
2%
Stryker Corp
NYSE:SYK
Additional Paid In Capital
$2.4B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
7%
Abbott Laboratories
NYSE:ABT
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Additional Paid In Capital
$9.4B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
13%
No Stocks Found

Myomo Inc
Glance View

Market Cap
208.2m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
3.85 USD
Overvaluation 38%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Additional Paid In Capital?
Additional Paid In Capital
105.8m USD

Based on the financial report for Sep 30, 2024, Myomo Inc's Additional Paid In Capital amounts to 105.8m USD.

What is Myomo Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
13%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Myomo Inc have been 6% over the past three years , 13% over the past five years .

Back to Top